{"id":16867,"date":"2022-04-04T17:34:09","date_gmt":"2022-04-04T12:04:09","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=16867"},"modified":"2024-09-18T13:23:00","modified_gmt":"2024-09-18T07:53:00","slug":"lag-3-next-generation-cancer-immunotherapy","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy","title":{"rendered":"LAG 3: A Promising Next Generation Cancer Immunotherapy"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a35a3eed9fe3\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a35a3eed9fe3\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#Biological_Characteristics_of_LAG_3_Immunotherapy\" >Biological Characteristics of LAG 3 Immunotherapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#LAG_3_Blockade_in_Cancer\" >LAG 3 Blockade in Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#LAG_3_Immunotherapy_Market\" >LAG 3 Immunotherapy Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#Novel_Emerging_Next-Generation_LAG_3_Immunotherapy\" >Novel &amp; Emerging Next-Generation LAG 3 Immunotherapy<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#MGD013_MacroGenics\" >MGD013: MacroGenics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#LAG525_Novartis\" >LAG525: Novartis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#Relatlimab_BMS-986016_Bristol-Myers_Squibb\" >Relatlimab (BMS-986016): Bristol-Myers Squibb<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#Eftilagimod_Alpha_IMP321_Immutep\" >Eftilagimod Alpha (IMP321): Immutep<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#MK-4280_Merck\" >MK-4280: Merck<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#REGN3767_Regeneron\" >REGN3767: Regeneron<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#FS118_F-star_Therapeutics\" >FS118: F-star Therapeutics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#XmAb22841_Xencor\" >XmAb22841: Xencor<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#INCAGN2385_Incyte_BiosciencesAgenus\" >INCAGN2385: Incyte Biosciences\/Agenus<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#Unmet_Needs_in_LAG_3_Immunotherapy_Treatment_Landscape\" >Unmet Needs in LAG 3 Immunotherapy Treatment Landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#Way_Ahead\" >Way Ahead<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts the body&#8217;s natural defenses to fight cancer. Cancer immunotherapy (CI) is recently advancing at a rapid pace and can be considered as the \u201cfifth pillar\u201d of cancer treatment, joining the ranks of radiation, cytotoxic chemotherapy, surgery, and targeted therapy. Cancer immunotherapy has sparked interest in involving antibodies to inhibitory immune checkpoint molecules. Lymphocyte Activation Gene 3 (LAG 3) is highly expressed in various types of tumor-infiltrating lymphocytes (TILs) and participates in the immune escape mechanism of tumors. Therefore, LAG 3 Immunotherapy can be used as an indicator of tumor prognosis and a target of tumor therapy. LAG 3 stands for Lymphocyte Activation Gene 3 or CD223, a gene encoding for a protein, which is involved in the regulation of the immune system.<\/p>\n\n\n\n<p>LAG 3 is a cell-surface molecule expressed on effector T cells and regulatory T cells (Tregs) and functions to control T-cell response, activation, and growth. Preclinical studies indicate that inhibition of LAG 3 may restore the effector function of exhausted T cells and potentially promote an anti-tumor response. Early research demonstrates that targeting LAG 3 in combination with other potentially <a href=\"https:\/\/www.delveinsight.com\/blog\/tigit-inhibitor-landscape\">complementary immune checkpoints<\/a> may be a key strategy to more effectively potentiate anti-tumor immune activity. Protein structure and function of LAG 3 Immunotherapy.<\/p>\n\n\n\n<p>The process of T cell inactivation and death are present both in cancer and chronic infection. As a co-inhibitory receptor of PD- 1, LAG 3 is highly expressed in chronic virus infection and various tumors. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-antagonist-pipeline-insight\">high expression of LAG 3<\/a> is also associated with autoimmune diseases, tumors, and chronic toxic infectious diseases. The rapid development of immuno-oncology (I-O) therapies such as LAG 3 Immunotherapy for multiple tumor types has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-biological-characteristics-of-lag-3-immunotherapy\"><span class=\"ez-toc-section\" id=\"Biological_Characteristics_of_LAG_3_Immunotherapy\"><\/span><strong>Biological Characteristics of LAG 3 Immunotherapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Immunosuppressive receptor molecules play an important role in the maintenance of immune homeostasis. When T lymphocytes are activated to a certain extent, immunosuppressive molecules, such as LAG 3, CTLA-4, and <a href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pdl-1-immune-check-point-inhibitors-a-prodigious-revolution-in-cancer-treatment\">PD-1<\/a> are expressed to maintain the immune response in a stable state. LAG 3 Immunotherapy works by LAG 3 molecule blocking the signal transduction pathway of T cell activation; however, the intracellular segment of the LAG 3 molecule produces immunosuppressive signals, which have been found to regulate CD4+T cell activity. LAG 3 Immunotherapy regulates the immune response of T cells in three ways:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Firstly, it directly inhibits the proliferation and activation of T cells via negative regulation of T cells.<\/li><li>Secondly, it can promote the inhibitory function of Tregs, and the T cell response can then be indirectly inhibited.<\/li><li>Thirdly, it can prevent T cell activation by regulating the function of APCs.<\/li><\/ul>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04170129\/LAG-3.png\" alt=\"Next-Generation LAG 3 Immunotherapy\" class=\"wp-image-16874\" width=\"887\" height=\"423\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04170129\/LAG-3.png 887w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04170129\/LAG-3-300x143.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04170129\/LAG-3-150x72.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04170129\/LAG-3-768x366.png 768w\" sizes=\"(max-width: 887px) 100vw, 887px\" \/><figcaption><strong>Next-Generation LAG 3 Immunotherapy<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lag-3-blockade-in-cancer\"><span class=\"ez-toc-section\" id=\"LAG_3_Blockade_in_Cancer\"><\/span><strong>LAG 3 Blockade in Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>LAG 3 Immunotherapy aids in regulating the proliferation, cytokine production, and\/or cytolytic functions of T cells through its cytoplasmic domain. Although most of the molecular mechanisms remain poorly understood, it is known that LAG 3 recognition of stable peptide- MHC-II complexes is critical for activity. Consequently, LAG 3 expression signals that ongoing responses are active at the inflammatory site (i.e. the TME). The rationale for targeting LAG 3 is based on the presence of a pre-existing immune response.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lag-3-immunotherapy-market\"><span class=\"ez-toc-section\" id=\"LAG_3_Immunotherapy_Market\"><\/span><strong>LAG 3 Immunotherapy Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Cancer immunotherapy and tumor microenvironment have been at the forefront of research over the past decades. Targeting immune checkpoints, especially <a href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pdl-1-immune-check-point-inhibitors-a-prodigious-revolution-in-cancer-treatment\">programmed death 1 (PD-1)\/programmed death-ligand 1 (PD- L1)<\/a> has made a breakthrough in treating advanced malignancies. However, the low response rate brings a daunting challenge, changing the focus to dig deeply into the tumor microenvironment for alternative therapeutic targets. Strikingly, the <a href=\"https:\/\/www.delveinsight.com\/blog\/tigit-inhibitor-landscape\">inhibitory immune checkpoint<\/a> for LAG 3 Immunotherapy holds considerable potential.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"675\" height=\"150\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/28173038\/Anticipated-LAG-3-Immunotherapy-Market-Size-in-the-7MM-2035.png\" alt=\"LAG-3-Next Generation Immunotherapy Market Size\" class=\"wp-image-17801\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/28173038\/Anticipated-LAG-3-Immunotherapy-Market-Size-in-the-7MM-2035.png 675w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/28173038\/Anticipated-LAG-3-Immunotherapy-Market-Size-in-the-7MM-2035-300x67.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/28173038\/Anticipated-LAG-3-Immunotherapy-Market-Size-in-the-7MM-2035-150x33.png 150w\" sizes=\"(max-width: 675px) 100vw, 675px\" \/><figcaption><strong>LAG-3-Next Generation Immunotherapy Market Size<\/strong><\/figcaption><\/figure>\n\n\n\n<p>According to Delveinsight\u2019s analysis, the market is expected to show positive growth due to the launch of potential upcoming therapies in the target LAG 3 Immunotherapy in the coming years and as per&nbsp; DelveInsight&#8217;s analysts, the LAG 3 Immunotherapy market size in the <strong>7MM <\/strong>countries is anticipated to increase and rise up to approximately <strong>6 Billion USD <\/strong>with a significant <strong>CAGR <\/strong>by <strong>2035<\/strong>. Moreover, the US will occupy the maximum market share in the overall LAG 3 Immunotherapy market size in 2035.<\/p>\n\n\n\n<p>The increase in <a href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape\">LAG 3 Immunotherapy market size<\/a> is a direct consequence of the increasing incident population of LAG 3 Next-generation Immunotherapies patients in the 7MM, along with the expected entry of premium-priced target-based drugs, which will put a significant impact on the LAG 3 Immunotherapy market size.<\/p>\n\n\n\n<p>Currently, numerous trials are undergoing different indications for target LAG 3 Immunotherapy. The major indications that are anticipated to show a better outcome by the launch of novel drugs include <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-breast-cancer-pipeline-insight\">Breast Cancer<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-carcinoma-nsclc-market\">NSCLC<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-cancer-market\">Gastric Cancer<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastroesophageal-adenocarcinoma-market\">Gastroesophageal Junction Cancer<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/melanoma-pipeline-insight\">Melanoma<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/colorectal-cancer-crc-market\">Colorectal Cancer,<\/a> <a href=\"https:\/\/www.delveinsight.com\/report-store\/head-and-neck-cancer-hnc-pipeline-insight\">Head and Neck Cancer<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-pipeline-insight\">Multiple Myeloma<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novel-emerging-next-generation-lag-3-immunotherapy\"><span class=\"ez-toc-section\" id=\"Novel_Emerging_Next-Generation_LAG_3_Immunotherapy\"><\/span><strong>Novel &amp; Emerging Next-Generation LAG 3 Immunotherapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape\">emerging trend in the Next-generation LAG 3 Immunotherapies<\/a> with continuous headway movement along with new emerging technologies for the development of targeted therapies is anticipated to give rise to better therapeutic alternatives. Key oncology players, such as <strong>MacroGenics, Zai Lab, Novartis, Bristol-Myers Squibb, Ono Pharmaceuticals, Immutep, Regeneron, Xencor, F-star Therapeutics<\/strong>, <strong>Merck Sharp &amp; Dohme, Crescendo Biologics, MICROBIO Group, Symphogen, Avacta, Abeome Corporation,<\/strong> etc. are involved in developing novel target LAG 3 Immunotherapies in treatment of various oncology indications. The expected launch of emerging therapies, such as <strong>MGD013, LAG525, Relatlimab, MK-4280, Eftilagimod Alpha, REGN3767, XmAb22841,<\/strong> and other treatments, would lead to a significant increase in the LAG 3 Immunotherapy market size in the coming years.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04165526\/Pioneers-Developing-Next-Generation-LAG-3-Immunotherapy.png\" alt=\"Pioneers Developing Next-Generation LAG 3 Immunotherapy\" class=\"wp-image-16870\" width=\"826\" height=\"295\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04165526\/Pioneers-Developing-Next-Generation-LAG-3-Immunotherapy.png 826w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04165526\/Pioneers-Developing-Next-Generation-LAG-3-Immunotherapy-300x107.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04165526\/Pioneers-Developing-Next-Generation-LAG-3-Immunotherapy-150x54.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04165526\/Pioneers-Developing-Next-Generation-LAG-3-Immunotherapy-768x274.png 768w\" sizes=\"(max-width: 826px) 100vw, 826px\" \/><figcaption><strong>Key Oncology Players Developing LAG 3 Immunotherapies<\/strong><\/figcaption><\/figure>\n\n\n\n<p>There are many pipeline LAG 3 Immunotherapies in different phases of development under clinical trials, which include &#8211;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mgd013-macrogenics\"><span class=\"ez-toc-section\" id=\"MGD013_MacroGenics\"><\/span><strong>MGD013: MacroGenics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>MGD013<\/strong> which is currently being developed by <strong>MacroGenics<\/strong> is an IgG4\u03ba bispecific DART molecule that binds to PD-1 and LAG 3 concomitantly or independently and disrupts non-redundant inhibitory pathways to restore shattered T-cell function further. The drug is the first in a series of product candidates that distinguish in the multiple immune regulatory targets. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-antagonist-pipeline-insight\">LAG 3 Immunotherapy<\/a> is currently being evaluated in a <strong>Mid-phase study, First-in-human, Open-label,<\/strong> in which the dose and schedule have been established and dose-expansion has been initiated in up to nine tumor types. The study is anticipated to be completed by <strong>July 2022.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-lag525-novartis\"><span class=\"ez-toc-section\" id=\"LAG525_Novartis\"><\/span><strong>LAG525: Novartis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>LAG525\/IMP701<\/strong> which is under development by <strong>Novartis <\/strong>is an investigational immunotherapy being developed to potentially treat a range of solid tumors. The drug is a humanized form of IMP701 and is currently being evaluated in five <strong>Phase I <\/strong>and <strong>Phase II clinical trials <\/strong>in combination with Novartis\u2019 PD-1 inhibitor spartalizumab for the treatment of various cancers. The company has also announced the regulatory submission of the drug in <strong>2023<\/strong>. A randomized, open-label study evaluating the efficacy and safety of novel <strong>Spartalizumab (PDR001).<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-relatlimab-bms-986016-bristol-myers-squibb\"><span class=\"ez-toc-section\" id=\"Relatlimab_BMS-986016_Bristol-Myers_Squibb\"><\/span><strong>Relatlimab (BMS-986016): Bristol-Myers Squibb<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Relatlimab (previously known as BMS-986016) is cancer immunotherapy being developed by Bristol-Myers Squibb (BMS). The treatment has already shown benefits in melanoma patients and is also being tested in other cancers. The drug is in <strong>Phase II\/III <\/strong>clinical-stage developmental trial in patients with multiple malignancies. LAG 3 Immunotherapy uses the body\u2019s own immune system to fight cancer, instead of directly attacking cancer cells. Recently in <strong>March 2021,<\/strong> the company announced <strong>RELATIVITY-047,<\/strong> a trial evaluating <strong>anti-LAG 3 antibodies Relatlimab<\/strong> and <strong>Opdivo (nivolumab)<\/strong> in patients with previously <a href=\"https:\/\/www.delveinsight.com\/report-store\/untreated-metastatic-or-unresectable-melanoma-pipeline-insight\">untreated metastatic or unresectable melanoma<\/a>, meeting the primary endpoint of progression-free survival.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-eftilagimod-alpha-imp321-immutep\"><span class=\"ez-toc-section\" id=\"Eftilagimod_Alpha_IMP321_Immutep\"><\/span><strong>Eftilagimod Alpha (IMP321): Immutep<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Eftilagimod alpha (IMP321) is being developed by <strong>Immutep <\/strong>in the <strong>Phase II <\/strong>developmental stage. It is a soluble dimeric recombinant form of LAG 3 Immunotherapy and is a first-in-class antigen-presenting cell activator under clinical development. By stimulating dendritic cells through MHC class II molecules, IMP321 was proven to induce sustained immune responses. Combining active immunotherapy with a standard cytotoxic chemotherapy regimen represents a promising novel strategy that might lead to therapeutic improvements in <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-breast-cancer-pipeline-insight\">metastatic breast cancer<\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mk-4280-merck\"><span class=\"ez-toc-section\" id=\"MK-4280_Merck\"><\/span><strong>MK-4280: Merck<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>MK-4280<\/strong> is co-developed by <strong>Immutep <\/strong>and <strong>Merck <\/strong>in <strong>Phase II <\/strong>developmental stage. It is a humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG 3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-LAG 3 monoclonal antibody MK-4280 binds to LAG 3 expressed on <a href=\"https:\/\/www.delveinsight.com\/report-store\/tumor-infiltrating-lymphocytes-market\">tumor-infiltrating lymphocytes (TILs)<\/a> and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG 3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T cells. Its expression on TILs is associated with tumor-mediated immune suppression.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regn3767-regeneron\"><span class=\"ez-toc-section\" id=\"REGN3767_Regeneron\"><\/span><strong>REGN3767: Regeneron<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>REGN3767 <\/strong>is an immune checkpoint being developed by <strong>Regeneron <\/strong>in <strong>Phase I<\/strong> for the treatment of both solid tumors and blood cancers. This drug is based on Regeneron\u2019s proprietary <strong>VelocImmune technology <\/strong>which yields optimized fully human antibodies. The immune system destroys infected or abnormal cells, including cancer cells, by activating specific T-cells.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-fs118-f-star-therapeutics\"><span class=\"ez-toc-section\" id=\"FS118_F-star_Therapeutics\"><\/span><strong>FS118: F-star Therapeutics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>FS118<\/strong> is a <strong>Phase II<\/strong> developmental product by <strong>F-star Therapeutics<\/strong>. It is a potential product candidate for the treatment of resistant and refractory cancer. It consists of a tetravalent and bispecific antibody developed to overcome tumor evasion mechanisms promoted by two highly immunosuppressive molecules: LAG-3 (Lymphocyte-Activation Gene 3) and PD-L1 (Programmed Death-Ligand 1). In a Phase I study in patients with advanced cancer and resistance to checkpoint therapy, FS118 administration showed good tolerability and encouraging signs of clinical activity in heavily pre-treated patients who had acquired resistance to prior checkpoint therapy. In <strong>January 2021<\/strong>, F-star was granted a composition of matter patent for FS118.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-xmab22841-xencor\"><span class=\"ez-toc-section\" id=\"XmAb22841_Xencor\"><\/span><strong>XmAb22841: Xencor<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Xencor,<\/strong> which is developing <strong>XmAb22841<\/strong>, is in <strong>Phase I<\/strong> developmental stage. It is a bispecific antibody that usually <a href=\"https:\/\/www.delveinsight.com\/blog\/tigit-inhibitor-landscape\">targets immune checkpoint receptors<\/a> CTLA-4 and LAG-3, and it is designed to promote tumor-selective T-cell activation. This drug is based on Xencor\u2019s XmAb technology. Xencors\u2019 XmAb bispecific Fc domain serves as the scaffold for these two antigen-binding domains and confers long circulating half-life, stability, and ease of manufacture. In January 2021, Xencor and MD Anderson entered a strategic collaboration to develop the drug for the potential treatment of patients with cancer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"INCAGN2385_Incyte_BiosciencesAgenus\"><\/span><strong>INCAGN2385: Incyte Biosciences\/Agenus<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>INCAGN2385,<\/strong> in <strong>Phase I\/II stage<\/strong>, is being developed by <strong>Incyte Biosciences\/Agenus<\/strong>. It is a LAG-3 inhibitor that was discovered within Incytes\u2019 antibody discovery alliance with Agenus. LAG-3 is a cell surface receptor that negatively regulates antigen-specific T-cell responses. The LAG-3 pathway has been identified as a potential barrier to productive tumor-specific T-cell immunity generated by PD-1\/PDL-1 blockade.<\/p>\n\n\n\n<p><strong><em>To Get Rich Insights on the Market of LAG 3 Targeted Therapies, Visit our Infographics @ <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/infographics\/lag-3-next-generation-immunotherapy-competitive-landscape\"><strong><em>LAG 3 Next-Generation Immunotherapy Market<\/em><\/strong><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Unmet_Needs_in_LAG_3_Immunotherapy_Treatment_Landscape\"><\/span><strong>Unmet Needs in LAG 3 Immunotherapy Treatment Landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>There are several unmet needs still present in the&nbsp; LAG 3 Immunotherapy treatment landscape, which includes some of the following &#8211;<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>The major challenge in the LAG 3 Immunotherapy market is the need to develop agents that are unfailingly effective in the majority of patients and tumor types.<\/li><li>LAG 3 Immunotherapy development is costly, which even tends to affect the R&amp;D activities of the companies because of lack of funding, so definitely there\u2019s a need to develop therapies that are affordable.<\/li><li>One of the major limitations of cancer immunotherapy is the availability of tumor-specific antigens (TSAs) which are also known as \u201cneoantigens\u201d are mainly expressed by tumor cells.<\/li><li>The factor that is used to evaluate cancer immunotherapies should be distinct from those used to assess response to chemotherapy and other cytotoxic agents.<\/li><\/ul>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04173130\/LAG-3-Next-Generation-Immunotherapy-Market-Assessment-1024x256.png\" alt=\"LAG-3-Next Generation Immunotherapy Market Assessment\" class=\"wp-image-16884\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04173130\/LAG-3-Next-Generation-Immunotherapy-Market-Assessment-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04173130\/LAG-3-Next-Generation-Immunotherapy-Market-Assessment-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04173130\/LAG-3-Next-Generation-Immunotherapy-Market-Assessment-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04173130\/LAG-3-Next-Generation-Immunotherapy-Market-Assessment-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04173130\/LAG-3-Next-Generation-Immunotherapy-Market-Assessment-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04173130\/LAG-3-Next-Generation-Immunotherapy-Market-Assessment-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04173130\/LAG-3-Next-Generation-Immunotherapy-Market-Assessment.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-way-ahead\"><span class=\"ez-toc-section\" id=\"Way_Ahead\"><\/span><strong>Way Ahead<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Although the complete biological processes of LAG 3 Immunotherapy are yet to be fully discovered, many clinical trials are under evaluation in early-stage followed by preclinical and discovery stages. The middle-to-late stage also encompasses many clinical trials that are under evaluation. Moreover, the emerging trends in Next-generation LAG-3 Immunotherapies and the addition of new emerging technologies for the development of targeted LAG-3 immunotherapy are anticipated to revolutionize cancer treatment in the coming years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1649070894458\"><strong class=\"schema-faq-question\"><strong>What does LAG-3 mean?<\/strong><\/strong> <p class=\"schema-faq-answer\">Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint. receptor protein found on the cell surface of effector T cells and. regulatory T cells (Tregs).<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1649070935543\"><strong class=\"schema-faq-question\"><strong>How does LAG-3 work?<\/strong><\/strong> <p class=\"schema-faq-answer\">LAG-3 on Treg cells inhibits DC proliferation and maturation through the engagement with MHC-II, which is mediated by an ITAM suppressive signaling pathway.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1649070974156\"><strong class=\"schema-faq-question\"><strong>What are some of the key LAG-3 Next-Generation Immunotherapy pioneers proactively involved in developing cancer treatment therapies?<\/strong><\/strong> <p class=\"schema-faq-answer\">Key oncology players, such as <strong>MacroGenics, Zai Lab, Novartis, Bristol-Myers Squibb, Ono Pharmaceuticals, Immutep, Regeneron, Xencor, F-star Therapeutics, Merck Sharp &amp; Dohme, Crescendo Biologics, MICROBIO Group, Symphogen, Avacta, Abeome Corporation, etc. <\/strong>are involved in developing novel target LAG 3 Immunotherapies in treatment of various oncology indications.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts the body&#8217;s natural defenses to fight cancer. Cancer immunotherapy (CI) is recently advancing at a rapid pace and can be considered as the \u201cfifth pillar\u201d of cancer treatment, joining the ranks of radiation, cytotoxic chemotherapy, surgery, and targeted therapy. Cancer immunotherapy has [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":16869,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19216,346,19215,454,3069,457],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-16867","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-lag-3","tag-lag-3-antagonists","tag-lymphocyte-activation-gene-3","tag-pd-1-and-pd-l-1-inhibitors","tag-pd-1-inhibitor","tag-pd-1pdl-1","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Next-generation LAG-3 Immunotherapies Cancer Treatment Landscape<\/title>\n<meta name=\"description\" content=\"The development of targeted LAG-3 immunotherapy is anticipated to revolutionize cancer treatment in the coming years, companies in the market\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Next-generation LAG-3 Immunotherapies Cancer Treatment Landscape\" \/>\n<meta property=\"og:description\" content=\"The development of targeted LAG-3 immunotherapy is anticipated to revolutionize cancer treatment in the coming years, companies in the market\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-04T12:04:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T07:53:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04165425\/LAG-3-The-Future-of-Cancer-Immunotherapy.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Next-generation LAG-3 Immunotherapies Cancer Treatment Landscape","description":"The development of targeted LAG-3 immunotherapy is anticipated to revolutionize cancer treatment in the coming years, companies in the market","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy","og_locale":"en_US","og_type":"article","og_title":"Next-generation LAG-3 Immunotherapies Cancer Treatment Landscape","og_description":"The development of targeted LAG-3 immunotherapy is anticipated to revolutionize cancer treatment in the coming years, companies in the market","og_url":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-04-04T12:04:09+00:00","article_modified_time":"2024-09-18T07:53:00+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04165425\/LAG-3-The-Future-of-Cancer-Immunotherapy.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy","url":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy","name":"Next-generation LAG-3 Immunotherapies Cancer Treatment Landscape","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04165425\/LAG-3-The-Future-of-Cancer-Immunotherapy.png","datePublished":"2022-04-04T12:04:09+00:00","dateModified":"2024-09-18T07:53:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The development of targeted LAG-3 immunotherapy is anticipated to revolutionize cancer treatment in the coming years, companies in the market","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy#faq-question-1649070894458"},{"@id":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy#faq-question-1649070935543"},{"@id":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy#faq-question-1649070974156"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04165425\/LAG-3-The-Future-of-Cancer-Immunotherapy.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04165425\/LAG-3-The-Future-of-Cancer-Immunotherapy.png","width":772,"height":482,"caption":"LAG 3 - The Future of Cancer Immunotherapy"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy#faq-question-1649070894458","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy#faq-question-1649070894458","name":"What does LAG-3 mean?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint. receptor protein found on the cell surface of effector T cells and. regulatory T cells (Tregs).","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy#faq-question-1649070935543","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy#faq-question-1649070935543","name":"How does LAG-3 work?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"LAG-3 on Treg cells inhibits DC proliferation and maturation through the engagement with MHC-II, which is mediated by an ITAM suppressive signaling pathway.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy#faq-question-1649070974156","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/lag-3-next-generation-cancer-immunotherapy#faq-question-1649070974156","name":"What are some of the key LAG-3 Next-Generation Immunotherapy pioneers proactively involved in developing cancer treatment therapies?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Key oncology players, such as <strong>MacroGenics, Zai Lab, Novartis, Bristol-Myers Squibb, Ono Pharmaceuticals, Immutep, Regeneron, Xencor, F-star Therapeutics, Merck Sharp &amp; Dohme, Crescendo Biologics, MICROBIO Group, Symphogen, Avacta, Abeome Corporation, etc. <\/strong>are involved in developing novel target LAG 3 Immunotherapies in treatment of various oncology indications.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/04165425\/LAG-3-The-Future-of-Cancer-Immunotherapy-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">LAG 3<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">LAG-3 Antagonists<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lymphocyte Activation Gene 3<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1 inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-1\/PDL-1<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">LAG 3<\/span>","<span class=\"advgb-post-tax-term\">LAG-3 Antagonists<\/span>","<span class=\"advgb-post-tax-term\">Lymphocyte Activation Gene 3<\/span>","<span class=\"advgb-post-tax-term\">PD-1 and PD-L 1 inhibitors<\/span>","<span class=\"advgb-post-tax-term\">PD-1 inhibitor<\/span>","<span class=\"advgb-post-tax-term\">PD-1\/PDL-1<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Apr 4, 2022","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Apr 4, 2022 5:34 pm","modified":"Updated on Sep 18, 2024 1:23 pm"},"featured_img_caption":"LAG 3 - The Future of Cancer Immunotherapy","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=16867"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16867\/revisions"}],"predecessor-version":[{"id":29598,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16867\/revisions\/29598"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/16869"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=16867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=16867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=16867"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=16867"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=16867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}